Close menu




October 19th, 2022 | 13:52 CEST

Biotech funds looking over their shoulders: Bavarian Nordic, Cardiol Therapeutics, Valneva

  • Biotechnology
Photo credits: pixabay.com

A recent study by Accenture shows that consumers are not willing to reduce their spending on health and wellness - even if things are not going well economically. Despite uncertainties, respondents see spending in the areas of "health" and "fitness" as "essential." Those who pay for these areas are also likely to want to exhaust all options when it comes to health insurance benefits, such as medications and vaccines. Informed patients and consumers put pressure on their doctors when new therapies are available. Health insurers, who are also in competition with each other, are taking this into account. We highlight three biotech stocks and do the investment check.

time to read: 3 minutes | Author: Nico Popp
ISIN: BAVARIAN NOR NAM. DK 10 | DK0015998017 , CARDIOL THERAPEUTICS | CA14161Y2006 , VALNEVA SE EO -_15 | FR0004056851

Table of contents:


    Bavarian Nordic: A good mix of substance and fantasy

    The share of Bavarian Nordic was recently kissed awake again. The reason: several countries, including the German government, are buying more vaccine doses against monkeypox. At the same time, the Company has reported that a COVID-19 vaccine candidate, intended as a booster, is still showing a robust immune response in several Corona variants after six months. Also at a clinical stage is a vaccine against the respiratory syncytial virus (RSV), which can cause lower respiratory tract disease. There is no vaccine yet, though a first regulatory filing is expected in the second half of the year. The market for RSV vaccines has the potential to be worth billions.

    Bavarian Nordic already has vaccines against smallpox, Ebola, rabies, TBE and monkeypox on the market. The share, therefore, also offers a balanced mix of growth opportunities and continuous cash flows. This is also the view of analysts. On average, the seven analysts currently covering the share give it a "buy" recommendation. The average price target is around 88% above the current price. Even the price target of the most pessimistic analyst still sees a potential of about 30%. Now that the share has come back after its monkeypox hype, investors can again consider an entry. However, investors should keep in mind that setbacks in clinical trials cannot be ruled out.

    Cardiol Therapeutics: Study shows positive signals

    Looking at the performance of the Cardiol Therapeutics share, one might think that the stock had already suffered such a setback - the share has been unstoppable for months and is now a penny stock again. Yet Cardiol Therapeutics is still considered a beacon of hope for inflammatory diseases of the heart. Less than a year ago, the Company raised around USD 50 million in the course of a capital increase. At that time, the price per unit was USD 3.07. Today, the stock is trading at USD 0.61 on the Nasdaq. Operational setbacks since then? None whatsoever!

    A few weeks ago, Cardiol Therapeutics presented preclinical results at the annual scientific compendium of the Heart Failure Society of America. Their basic tenor is that the compound CardiolRx™ is capable of protecting cardiac function and provides antifibrotic effects. "Our research colleagues at Houston Methodist DeBakey Heart & Vascular Center have already shown that CardiolRx™ preserves cardiac function in a preclinical model of heart failure. The results of the present study provide further evidence of CardiolRx's cardioprotective properties, suggesting antifibrotic mechanisms with therapeutic potential in heart failure," said Andrew Hamer, M.D., Chief Medical Officer and Head of Research and Development at Cardiol Therapeutics. Given that cardiovascular disease is a common condition and such symptoms may also be associated with severe courses of COVID-19, investors should not write off the share of Cardiol Therapeutics. It is quite possible that there are reasons behind the share sell-off that have nothing to do with Cardiol Therapeutics. At the moment, the share seems to be bottoming out - but the stock is still not for the faint of heart. Hardened speculators with adequate money and risk management can already take a look at the value again.

    Valneva: Biotech professionals grab the falling knife

    The Valneva share also recently made a comeback. After the French company's Corona plans turned into a fiasco, the Company is now focusing on vaccines against chikungunya fever and Lyme disease. Major investors have also taken a liking to the Company and recently subscribed to a capital increase of EUR 100 million. In addition to existing shareholders, biotech investor Deep Track Capital is also said to have taken a stake and is rumored to have subscribed to around half of the new shares. The vote of confidence from industry experts should also reassure existing shareholders. As with Cardiol Therapeutics, whether the share price will find a bottom at current levels remains to be seen.


    The entry of the biotech professionals from Deep Track Capital, despite the disastrous share price performance of Valneva in recent months, should also encourage former biotech hopefuls, such as Cardiol Therapeutics. As soon as clinical studies show success, hardened investors jump at the chance - and in the case of Deep Track Capital, they like to do so on a large scale. In the case of Cardiol Therapeutics, this is likely to be compounded by the fact that some investors who also held warrants in the Company have pulled the ripcord in recent months in challenging market conditions. However, there is still potential for innovative active ingredients and vaccines.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Nico Popp on November 30th, 2022 | 13:33 CET

    Advances in the fight against cancer: Arcus Biosciences, Gilead Sciences, Defence Therapeutics, BioNTech

    • Biotechnology
    • Covid19
    • Cancer

    Research studies from 2020 show that 72% of Germans fear cancer. However, very few people want to admit to these fears. But precisely because the subject is a big taboo, it is worth looking at the latest achievements in research. Many companies worldwide have long been fighting the epidemic - and making astonishing progress. Just recently, a US biotech announced encouraging study results. Other companies have yet to launch promising studies. We provide an overview and outline opportunities from an investor's perspective.

    Read

    Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

    Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

    • Biotechnology
    • Cancer
    • Investments

    Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.

    Read

    Commented by Fabian Lorenz on November 24th, 2022 | 12:40 CET

    New year, rising prices? BASF, BioNTech and Manuka Resources - Shares in check

    • Mining
    • Commodities
    • Biotechnology
    • chemicals

    As the stock market year 2022 draws to a close, we look ahead to 2023. New year, rising prices? That is what many stock market players are hoping for. The chances are that we will see rising indices again with the end of interest rate hikes in the coming year. Today, we look at three companies likely to attract attention in 2023. At BioNTech, the research pipeline is full to bursting, and there are numerous study results to come. BASF is attractive due to its low valuation and high dividend yield. However, analysts warn of a write-off risk. Manuka Ressources convinces with a profitable core business, and an exciting project in the field of critical raw materials could lead to a revaluation.

    Read